N
Neil H. Shusterman
Researcher at Endo International plc
Publications - 16
Citations - 9865
Neil H. Shusterman is an academic researcher from Endo International plc. The author has contributed to research in topics: Heart failure & Carvedilol. The author has an hindex of 10, co-authored 16 publications receiving 9675 citations. Previous affiliations of Neil H. Shusterman include University of Texas Southwestern Medical Center & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Milton Packer,Michael R. Bristow,Jay N. Cohn,Wilson S. Colucci,Michael B. Fowler,Edward M. Gilbert,Neil H. Shusterman +6 more
TL;DR: Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
Journal Article
The Effect of Carvedilol on Morbidity and Mortality in Patients With Chronic Heart Failure
Milton Packer,Michael R. Bristow,Jay N. Cohn,Wilson S. Colucci,Michael B. Fowler,Edward M. Gilbert,Neil H. Shusterman +6 more
TL;DR: In this paper, a double-blind, placebo-controlled, stratified program, in which patients were assigned to one of four treatment protocols on the basis of their exercise capacity, was presented.
Journal ArticleDOI
Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
Michael R. Bristow,Edward M. Gilbert,William T. Abraham,Kirkwood F. Adams,Michael B. Fowler,Ray E. Hershberger,Spencer H. Kubo,Kenneth A. Narahara,Henry Ingersoll,Steven K. Krueger,Sarah Young,Neil H. Shusterman +11 more
TL;DR: In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose- related reductions in mortality and hospitalization rate and was generally well tolerated.
Journal ArticleDOI
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure The PRECISE Trial
Milton Packer,Wilson S. Colucci,Jonathan Sackner-Bernstein,Chang Seng Liang,David A. Goldscher,Israel Freeman,Marrick L. Kukin,Vithal Kinhal,James E. Udelson,Marc Klapholz,Stephen S. Gottlieb,David L. Pearle,Robert J. Cody,John Gregory,Nikki E. Kantrowitz,Thierry H. LeJemtel,Sarah T. Young,Mary Ann Lukas,Neil H. Shusterman +18 more
TL;DR: In a multicenter trial as mentioned in this paper, patients with moderate to severe heart failure (6-minute walk distance, 150 to 450 m) and a left ventricular ejection fraction ≤ 0.35 at 31 centers were randomly assigned to either placebo or carvedilol for 6 months, while background therapy with digoxin, diuretics and an ACE inhibitor remained constant.
Journal ArticleDOI
Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program☆
Jose A. Joglar,Andre Acusta,Andre Acusta,Neil H. Shusterman,Neil H. Shusterman,Karthik Ramaswamy,Karthik Ramaswamy,Robert C. Kowal,Robert C. Kowal,Saverio J. Barbera,Saverio J. Barbera,Mohamed H. Hamdan,Mohamed H. Hamdan,Richard L. Page,Richard L. Page +14 more
TL;DR: In this article, the authors conducted a retrospective analysis of data from the US Carvedilol Heart Failure Trials Program and identified patients with atrial fibrillation (AF) at the time of enrollment.